drugset / Trial / NCT04857112
Study Evaluating Efficacy and Safety of Amiselimod (MT-1303) in Mild to Moderate Ulcerative Colitis
RandomizedParallel-groupDouble-blindTreatment
Summary
The study will assess the efficacy and safety of oral MT-1303 compared to placebo at 12 weeks as the induction treatment in subjects with active mild to moderate ulcerative colitis (UC), as well as maintenance treatment with open-label MT-1303 for up to 36 weeks.
Timeline
- Start
- 2021-09-29
- Primary completion
- 2024-09-03
- Completion
- 2024-11-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | amiselimod | Small molecule | 0.2 mg | Oral |
| Subject | amiselimod | Small molecule | 0.4 mg | Oral |